Uri  Weinberg net worth and biography

Uri Weinberg Biography and Net Worth

Insider of NovoCure
Dr. Uri Weinberg currently serves as Novocure’s Chief Science Officer overseeing early-stage research and development as well as the design and development stages of all clinical trials. Since joining Novocure in 2008, he has held several positions throughout his tenure with the company. Dr. Weinberg managed Novocure’s first clinical trial in lung cancer as well as the EF-14 clinical trial in newly diagnosed glioblastoma and built the company’s global Clinical Operations team in Switzerland. Prior to becoming Chief Science Officer in March 2020, Dr. Weinberg most recently held the position of Vice President of Clinical Development where he was responsible for expanding research activities, strengthening global clinical collaboration and initiating new discovery programs. Dr. Weinberg holds an M.D. Ph.D. from the Technion – Israel Institute of Technology.

What is Uri Weinberg's net worth?

The estimated net worth of Uri Weinberg is at least $729,801.96 as of January 5th, 2023. Dr. Weinberg owns 43,286 shares of NovoCure stock worth more than $729,802 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Weinberg may own. Learn More about Uri Weinberg's net worth.

How do I contact Uri Weinberg?

The corporate mailing address for Dr. Weinberg and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Uri Weinberg's contact information.

Has Uri Weinberg been buying or selling shares of NovoCure?

Uri Weinberg has not been actively trading shares of NovoCure during the last ninety days. Most recently, Uri Weinberg sold 8,143 shares of the business's stock in a transaction on Thursday, January 5th. The shares were sold at an average price of $116.14, for a transaction totalling $945,728.02. Following the completion of the sale, the insider now directly owns 43,286 shares of the company's stock, valued at $5,027,236.04. Learn More on Uri Weinberg's trading history.

Who are NovoCure's active insiders?

NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Pritesh Shah (Insider), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.

Are insiders buying or selling shares of NovoCure?

During the last twelve months, insiders at the medical equipment provider sold shares 10 times. They sold a total of 11,141 shares worth more than $188,910.17. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.

Information on this page was last updated on 11/1/2024.

Uri Weinberg Insider Trading History at NovoCure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2023Sell8,143$116.14$945,728.0243,286View SEC Filing Icon  
9/25/2020Sell15,250$103.35$1,576,087.5036,347View SEC Filing Icon  
See Full Table

Uri Weinberg Buying and Selling Activity at NovoCure

This chart shows Uri Weinberg's buying and selling at NovoCure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NovoCure Company Overview

NovoCure logo
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Read More

Today's Range

Now: $16.86
Low: $16.22
High: $17.35

50 Day Range

MA: $16.53
Low: $14.54
High: $18.57

2 Week Range

Now: $16.86
Low: $11.29
High: $24.74

Volume

673,942 shs

Average Volume

919,911 shs

Market Capitalization

$1.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71